PERP-BNasdaq StockholmMedical DevicesIFRS · SEK

Perpetua Medical

Perpetua Medical is a Swedish acquisition company focused on buying and owning profitable, product-oriented businesses in the healthcare sector. It operates through a decentralized group structure, with independent subsidiaries responsible for day-to-day operations and commercial decisions. The company is headquartered in Uppsala and its shares trade on Nasdaq First North Stockholm under the ticker PERP B.

Revenue5.2m SEK
+23.8 %y/y
Operating profit (EBIT)-2.5m SEK
−122.2 %y/y
EBIT margin-47.6%
−21.1 ppy/y
Net income1.2m SEK
+151.0 %y/y

Fiscal year 2025 · change from previous year

Development 2021–2025

-2,00002,0004,0006,0008,00010,000m SEK20212022: 8,816 m SEK2022: EBIT -19 m SEK20222023: 9.9 m SEK2023: EBIT -18 m SEK20232024: 4.2 m SEK2024: EBIT -1.1 m SEK20242025: 5.2 m SEK2025: EBIT -2.5 m SEK2025TTM 2026: EBIT -2.5 m SEKTTM-2.5
RevenueOperating profit (EBIT)TTM = last 12 months, not a full fiscal year

Business

Share of revenue
Healthcare acquisitions0 %

Buying and owning profitable healthcare companies as long-term holdings.

Medical technology operations100 %

Operating product-based healthcare businesses through subsidiaries.

Licensing and asset monetization0 %

Licensing and selling legacy products and related rights.

Customers

Perpetua Medical sells through its operating subsidiaries to healthcare-related customers that need specialized medical technology products and related commercial support. The customer base is therefore defined by the portfolio companies it owns, rather than by a single unified end market. In practice, buyers include hospitals, healthcare providers, distributors, and other commercial partners depending on the subsidiary and product line.

Healthcare product customers

Hospitals, clinics, and other healthcare users buying medical technology products from subsidiaries.

Distributors and channel partners

Partners that sell subsidiary products into local healthcare markets.

Licensing counterparties

Companies or partners that obtain rights to sell legacy products or assets.

Strategy

The company’s strategy is to acquire profitable, product-oriented healthcare businesses and hold them without a fixed exit horizon. It emphasizes a decentralized ownership model so each subsidiary can operate independently while the parent focuses on capital allocation and portfolio building. The reports also show a continued focus on building an acquisition pipeline and financing capacity to support future transactions.

Build and execute the acquisition pipelineShort term

Growth depends on completing new healthcare acquisitions and expanding the portfolio.

Maintain decentralized subsidiary ownershipMedium term

Independent operating companies are intended to preserve entrepreneurial focus and value creation.

Strengthen financing capacity for acquisitionsShort term

Acquisition-led growth requires access to capital for transactions and working capital.

Geography

Perpetua Medical is headquartered in Uppsala, Sweden, and is listed in Stockholm. The reports also reference U.S. market activity through licensing and divestment arrangements, showing that the company’s portfolio can have cross-border commercial exposure even when the parent is Swedish. Geography matters because subsidiary operations, customer access, and partner relationships can differ materially by market.

Risks

Perpetua Medical’s value depends heavily on the performance and valuation of its subsidiaries, which makes goodwill impairment and acquisition execution key risks. As an acquisition-led healthcare group, it is also exposed to deal timing, financing availability, and the commercial performance of the businesses it buys. Legacy asset disposals, partner dependence, and product-development uncertainty add further execution and valuation risk.

Sorted by severity
Goodwill impairmentHigh

Acquired businesses are tested at the subsidiary level and value depends on future cash flows.

Exposure: Goodwill and acquisition accounting

Acquisition execution riskHigh

The business model relies on finding, negotiating, and closing suitable healthcare targets.

Exposure: Pipeline and M&A process

Financing and dilution riskMedium

Acquisitions and portfolio expansion depend on access to equity capital.

Exposure: Share issues and transaction funding

Supplier and partner concentrationMedium

Subsidiaries may rely on a limited number of distributors or suppliers.

Exposure: Operating subsidiaries

Product development riskMedium

Portfolio companies may invest in products that do not meet technical or market expectations.

Exposure: Medical technology subsidiaries

Accounting

Judgemental items
Purchase price allocation

Acquisitions require estimates for customer contracts, goodwill, and discount rates.

Impact: Affects intangible assets and future amortization

Goodwill impairment testing

Recoverable value is based on five-year cash flow forecasts and key assumptions.

Impact: Can create large non-cash write-downs

Contingent consideration

Earn-outs depend on future results and additional share purchases, making valuation uncertain.

Impact: Affects liabilities and acquisition cost

Deferred purchase price receivables

Part of the legacy asset sale is payable over 24 months.

Impact: Creates credit and timing risk in reported assets

Publicly listed companies with a comparable business focus.

Last updated: 24/09/2026

Perpetua Medical (PERP-B) Revenue, Earnings & Financials 2025 – Clarifo